Lactate Suppresses Growth of Esophageal Adenocarcinoma Patient-Derived Organoids through Alterations in Tumor NADH/NAD+ Redox State

Biomolecules. 2024 Sep 22;14(9):1195. doi: 10.3390/biom14091195.

Abstract

Barrett's esophagus (BE) is a common precancerous lesion that can progress to esophageal adenocarcinoma (EAC). There are significant alterations in the esophageal microbiome in the progression from healthy esophagus to BE to EAC, including an increased abundance of a variety of lactate-producing bacteria and an increase of lactate in the tumor microenvironment, as predicted by metabolic modeling. The role of bacterial lactate in EAC is unknown. Here, we utilize patient-derived organoid (PDO) models of EAC and demonstrate that lactate inhibits the growth and proliferation of EAC PDOs through alterations in the tumor NADH/NAD+ redox state. Further RNA sequencing of EAC PDOs identifies ID1 and RSAD2 as potential regulatory molecules crucial in mediating lactate's ability to suppress glycolysis and proliferation. Gene ontology analysis also identifies the activation of inflammatory and immunological pathways in addition to alterations in the metabolic pathways in EAC PDOs exposed to lactate, suggesting a multi-faceted role for lactate in the pathogenesis of EAC.

Keywords: esophageal adenocarcinoma; lactate; tumor microenvironment.

MeSH terms

  • Adenocarcinoma* / metabolism
  • Adenocarcinoma* / pathology
  • Barrett Esophagus / metabolism
  • Barrett Esophagus / pathology
  • Cell Proliferation* / drug effects
  • Esophageal Neoplasms* / metabolism
  • Esophageal Neoplasms* / pathology
  • Glycolysis / drug effects
  • Humans
  • Lactic Acid* / metabolism
  • NAD* / metabolism
  • Organoids* / drug effects
  • Organoids* / metabolism
  • Oxidation-Reduction*
  • Tumor Microenvironment

Substances

  • NAD
  • Lactic Acid

Supplementary concepts

  • Adenocarcinoma Of Esophagus

Grants and funding

This work was supported by the Herbert Irving Comprehensive Cancer Center Support Grant P30CA013696 (JG, HN, SS), Mark L. Heaney and Florence and Florence and Herbert Irving Scholar Award (SS), AGA Research Scholar Award (JG), NIH P01CA098101 (HN, JG), NIH R01DK114436 (HN), NIH R01AA026297 (HN), NIH U54 CA163004 (JA), R01 CA238433 (JA), R01 CA255298 (JA), American Cancer Society PF-23 1151788-01-DMC (SF), NIH 5T32CA265828-02 (SF), and NIH L30CA264714 (SF).